Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey


escrs app advert

Flexible iris-fixated phakic lens in the treatment of moderate-to-high myopia: refractive, visual, and safety results after 5 years

Search Title by author or title

Session Details

Session Title: Phakic IOLs

Session Date/Time: Sunday 23/09/2018 | 08:00-10:00

Paper Time: 08:12

Venue: Room A3, Podium 1

First Author: : M.João PORTUGAL

Co Author(s): :    J. Costa   T. Monteiro   N. Franqueira   F. Correia           

Abstract Details


Surgical treatment of moderate to high myopia may involve several strategies. Implantation of a phakic intraocular lens (IOL) is the preferred option in younger patients. Artiflex® is a model of phakic, flexible, iris-fixated IOL. The aim of this study was to analyze the efficacy and safety of Artiflex® lens implant (Ophtec BV, Groningen, The Netherlands) for refractive correction of moderate to high myopia.


Hospital de Braga


We analyzed data from 94 of eyes of 54 patients undergoing Artiflex® lens implant for the correction of high myopia, between January 2009 and July 2013. The minimum follow-up time varied between 12 and 60 months and the parameters analyzed were: visual acuity without (UCVA) and with correction (BCVA); spherical equivalent; subjective refraction spherical and cylindrical; and endothelial cell count. The indexes for efficacy and safety were also calculated.


At 60 months, we obtained a significant improvement of 0,79 ± 0,19 on BCVA to 0,93 ± 0,15.; spherical equivalent decreased from -9,49 ± 3,11 to 0,02 ± 0,44 at 12 months and -0,02 ± 0,44 at 60 months. We obtained an average loss of endothelial cells of 2,01 % at 12 months, 2,71 % at 24 months, 5,22 % at 36 months, 7,95 % at 60 months, equivalent to an average annual loss of 1,59%.


The phakic intraocular lens Artiflex® is an effective, safe and stable treatment of moderate to high myopia. Annual follow-up careful it is mandatory to monitor the density of endothelial cells and other rare complications associated

Financial Disclosure:


Back to previous